PMID- 16635519
OWN - NLM
STAT- MEDLINE
DCOM- 20060525
LR  - 20181201
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 67
IP  - 5
DP  - 2006 May
TI  - Expression and antigenicity of survivin, an inhibitor of apoptosis family member, 
      in bladder cancer: implications for specific immunotherapy.
PG  - 955-9
AB  - OBJECTIVES: To assess the expression of survivin in transitional cell carcinoma 
      of the bladder and to study whether survivin is a transitional cell 
      carcinoma-specific antigen that could be a target for immunotherapy. Survivin, an 
      inhibitor of apoptosis family member, has been reported to be expressed in 
      various cancers but not in normal adult tissues. METHODS: Immunohistochemical 
      staining for survivin and human leukocyte antigen (HLA) class I was performed on 
      specimens from 88 patients who underwent transurethral resection and radical 
      cystectomy. To determine whether survivin was recognized as a tumor antigen by 
      the host immune system, we assessed anti-survivin antibodies in the sera of 52 
      patients and 18 healthy volunteers with an enzyme-linked immunosorbent assay 
      using recombinant survivin. RESULTS: Survivin and HLA class I were expressed in 
      77 (87.5%) and 59 (67.0%) of the 88 bladder cancer specimens, respectively, and 
      56 (63.6%) expressed both survivin and HLA class I. The absorbance values of 
      anti-survivin antibodies in patients with bladder cancer were significantly 
      greater than those in the healthy volunteers. A relationship was found between 
      the level of serum anti-survivin antibodies and the staining intensity of 
      survivin in the specimen. CONCLUSIONS: Survivin is expressed in carcinoma of the 
      bladder with high sensitivity. It is suggested that survivin is presented on HLA 
      class I molecules of antigen-presenting cells in 64% of patients with bladder 
      cancer. Therapeutic targeting of survivin in bladder cancer is a future 
      possibility.
FAU - Kitamura, Hiroshi
AU  - Kitamura H
AD  - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan. hkitamu@sapmed.ac.jp
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Honma, Ichiya
AU  - Honma I
FAU - Asanuma, Hiroko
AU  - Asanuma H
FAU - Nakazawa, Emiri
AU  - Nakazawa E
FAU - Shimozawa, Kumiko
AU  - Shimozawa K
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
FAU - Sato, Eiji
AU  - Sato E
FAU - Sato, Noriyuki
AU  - Sato N
FAU - Tsukamoto, Taiji
AU  - Tsukamoto T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060425
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Survivin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/blood/*immunology
MH  - Biomarkers, Tumor/blood/*immunology
MH  - Carcinoma, Transitional Cell/*immunology
MH  - Genes, MHC Class I/immunology
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/biosynthesis/immunology
MH  - Microtubule-Associated Proteins/biosynthesis/*immunology
MH  - Middle Aged
MH  - Neoplasm Proteins/biosynthesis/*immunology
MH  - Survivin
MH  - Urinary Bladder Neoplasms/*immunology
MH  - Urologic Surgical Procedures
EDAT- 2006/04/26 09:00
MHDA- 2006/05/26 09:00
CRDT- 2006/04/26 09:00
PHST- 2005/09/06 00:00 [received]
PHST- 2005/10/26 00:00 [revised]
PHST- 2005/11/23 00:00 [accepted]
PHST- 2006/04/26 09:00 [pubmed]
PHST- 2006/05/26 09:00 [medline]
PHST- 2006/04/26 09:00 [entrez]
AID - S0090-4295(05)01706-1 [pii]
AID - 10.1016/j.urology.2005.11.052 [doi]
PST - ppublish
SO  - Urology. 2006 May;67(5):955-9. doi: 10.1016/j.urology.2005.11.052. Epub 2006 Apr 
      25.